Ultimovacs Future Growth
Future criteria checks 3/6
Ultimovacs is forecast to grow earnings and revenue by 14.4% and 1.3% per annum respectively. EPS is expected to grow by 16.9% per annum. Return on equity is forecast to be 12% in 3 years.
Key information
14.4%
Earnings growth rate
16.9%
EPS growth rate
Biotechs earnings growth | 31.1% |
Revenue growth rate | 1.3% |
Future return on equity | 12.0% |
Analyst coverage | Low |
Last updated | 04 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 335 | 242 | 242 | 242 | 1 |
12/31/2025 | N/A | -140 | -143 | -145 | 2 |
12/31/2024 | 954 | 654 | 627 | 626 | 2 |
12/31/2023 | N/A | -189 | -190 | -190 | N/A |
9/30/2023 | N/A | -204 | -197 | -197 | N/A |
6/30/2023 | N/A | -186 | -197 | -197 | N/A |
3/31/2023 | N/A | -165 | -159 | -159 | N/A |
12/31/2022 | N/A | -168 | -168 | -168 | N/A |
9/30/2022 | N/A | -148 | -152 | -152 | N/A |
6/30/2022 | N/A | -153 | -145 | -145 | N/A |
3/31/2022 | N/A | -168 | -142 | -142 | N/A |
12/31/2021 | N/A | -165 | -126 | -126 | N/A |
9/30/2021 | N/A | -138 | -105 | -105 | N/A |
6/30/2021 | N/A | -126 | -102 | -102 | N/A |
3/31/2021 | N/A | -124 | -110 | -105 | N/A |
12/31/2020 | N/A | -121 | -114 | -108 | N/A |
9/30/2020 | N/A | -121 | -114 | -108 | N/A |
6/30/2020 | N/A | -108 | -102 | -97 | N/A |
3/31/2020 | N/A | -77 | -80 | -79 | N/A |
12/31/2019 | N/A | -61 | -63 | -63 | N/A |
9/30/2019 | N/A | -48 | -59 | -59 | N/A |
6/30/2019 | N/A | -48 | -57 | -56 | N/A |
3/31/2019 | N/A | -59 | -55 | -55 | N/A |
12/31/2018 | N/A | -55 | -51 | -50 | N/A |
9/30/2018 | N/A | -50 | -46 | -45 | N/A |
6/30/2018 | N/A | -42 | -38 | -38 | N/A |
3/31/2018 | N/A | -35 | -32 | -32 | N/A |
12/31/2017 | N/A | -33 | -27 | -27 | N/A |
12/31/2016 | N/A | -29 | N/A | -31 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 7UM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.6%).
Earnings vs Market: 7UM is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 7UM is expected to become profitable in the next 3 years.
Revenue vs Market: 7UM's revenue (1.3% per year) is forecast to grow slower than the German market (5.5% per year).
High Growth Revenue: 7UM's revenue (1.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 7UM's Return on Equity is forecast to be low in 3 years time (12%).